Elite Pharmaceuticals Inc. (ELTP)
OTCQB OTCQB Primary 
Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Percocet® (oxycodone hydrochloride and acetaminophen tablets, USP CII) 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Oxycodone HCl and acetaminophen is indicated for the relief of moderate to moderately severe pain.
Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today the shipment of its first lot of finished product from its new FDA-approved expanded campus. The new facility, located at 144 Ludlow Avenue in Northvale, New Jersey, includes packaging, inventory and warehouse space.
ELTP Stock Falls Following Q3 Earnings Decline, Revenue Down Y/Y
Elite Pharmaceuticals' third-quarter fiscal 2025 reports a revenue drop and a net loss. However, delayed shipments impact results.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
Conference Call Scheduled for Friday, February 14 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended December 31, 2024, which is the third quarter of the Company's fiscal year ending on March 31, 2025 ("Third Quarter"). Consolidated revenues for the three months ended December 31, 2024, were $14.4 million, a decrease of $1.2 million or approximately 8% as compared to the comparable period of the prior fiscal year.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
Financials for the Third Quarter of Fiscal Year 2025 Ended December 31, 2024 will be released on Thursday, February 13, 2025 Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2025 fiscal year will be released on Thursday, February 13, 2025. Elite's management will host a live conference call on Friday, February 14th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets
Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Norco® (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Hydrocodone and acetaminophen is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Two Smaller Companies Worthy of Your "Attention"
Here we highlight a small cap and a microcap with Zacks Outperform ratings.
Elite Pharmaceuticals' Stock Up Despite Q2 Earnings Decline
ELTP sees strong revenue growth despite a net loss, driven by new product launches and strategic acquisitions.
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Vyvanse® (Lisdexamfetamine Dimesylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Elite Pharmaceuticals, Inc. (ELTP) Q2 2025 Earnings Conference Call Transcript
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2025 Earnings Conference Call November 15, 2024 11:30 AM ET Company Participants Nasrat Hakim - President and CEO Carter Ward - CFO Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal Year 2025 Conference Call. At this time all lines have been placed on a listen-only mode.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information
Conference Call Scheduled for Friday, November 15 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended September 30, 2024, which is the second quarter of the Company's fiscal year ending on March 31, 2025 ("Second Quarter"). Consolidated revenues for the three months ended September 30, 2024, were $18.9 million, an increase of $4.7 million or approximately 33% as compared to the comparable period of the prior fiscal year.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024 Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2025 fiscal year will be released on Thursday, November 14, 2024. Elite's management will host a live conference call on Friday, November 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.
